Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

@article{Motzer2018NivolumabPI,
  title={Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.},
  author={Robert J Motzer and Nizar M. Tannir and D F Mcdermott and Osvaldo Ar{\'e}n Frontera and Bohuslav Melichar and Toni K Choueiri and Elizabeth R Plimack and Philippe Barth{\'e}l{\'e}my and Camillo Porta and Saby George and Thomas Powles and Frede N. Donskov and Victoria Neiman and Christian K. Kollmannsberger and Pamela Salman and Howard Gurney and Robert Edward Hawkins and Alain Mure Ravaud and Marc-Oliver Grimm and Sergio Bracarda and Carlos Henrique Barrios and Yoshihiko Tomita and Daniel E. Castellano and Brian I. Rini and Allen Chao-Lun Chen and Sabeen Mekan and Michael Brent McHenry and Megan Wind-Rotolo and Justin F Doan and P Sharma and Hans J. Hammers and Bernard Escudier},
  journal={The New England journal of medicine},
  year={2018},
  volume={378 14},
  pages={
          1277-1290
        }
}
BACKGROUND Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 139 CITATIONS, ESTIMATED 54% COVERAGE

Systemtherapie des Nierenzellkarzinoms

VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

  • Journal for immunotherapy of cancer
  • 2018
VIEW 9 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Laparoskopische Kolposuspension gegen Harninkontinenz bei Frauen

VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2018
2019

CITATION STATISTICS

  • 15 Highly Influenced Citations

  • Averaged 70 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Nivolumab in previously untreated melanoma without BRAF mutation.

  • The New England journal of medicine
  • 2015
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2017
VIEW 1 EXCERPT

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
VIEW 2 EXCERPTS

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2015
VIEW 3 EXCERPTS